glp-1 glucose GLP-1: Actions on Beta-cell Mass and Function GLP-1 for Weight Loss and

Tirzepatide Once Weekly for the Treatment of Obesity AMG 133 is a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule

However, substantial research is needed to expand their utility, optimize delivery methods, and improve patient outcomes

Understanding these mechanisms can help set realistic expectations

A licensed U.S

Semaglutide, tirzepatide, and high dose dulaglutide have been deemed to have very high likelihood of achieving adequate blood sugar control, while other GLP-1s have been deemed highly likely

Its critical to see your physician to screen for these common conditions and treat them if found. Additionally, Maselli recommends asking your healthcare professional if other medications you take list weight gain as a possible side effect